Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis.
Cannabinoids have been shown to have a beneficial effect in both animal models of multiple sclerosis (MS) and human disease, although the mechanisms of action are unclear. We examined expression of the major cannabinoid receptors [(CBRs) cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2)] and a key enzyme involved in synthesis of the endocannabinoid anandamide [N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD)] in autopsy brain samples from patients with MS. CB1 was expressed in neurons, injured axons, oligodendrocytes, macrophages/microglia, some astrocytes, endothelial cells, smooth muscle cells and pericytes. CB2 and NAPE-PLD were localized to cerebral endothelial cells, pericytes, smooth muscle cells, astrocytes and macrophages/microglia. NAPE-PLD immunoreactivity was also seen in neurons. Endothelial CB2 expression was greatest in chronic inactive plaques, and in areas was seen in segments of endothelium where the endothelial expression of adhesion molecules (VCAM-1 and ICAM-1) was focally undetectable, and was often expressed in areas of blood-brain barrier damage. Vascular density was increased in chronic active plaques and normal-appearing white matter compared with controls. These data support findings from animal models which suggest a role for the endocannabinoid system in the MS, particularly in the regulation of endothelial leukocyte adhesion and the cellular response to injury.
Clinical Neurobiology, Peninsula College of Medicine and Dentistry.
Hua
H
Zhang
David A
DA
Hilton
C Oliver
CO
Hanemann
John
J
Zajicek
D000199:Actins / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism; D001253:Astrocytes / Q000378:metabolism; D001808:Blood Vessels / Q000378:metabolism / Q000473:pathology; D001812:Blood-Brain Barrier / Q000473:pathology; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology*; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000145:classification / Q000473:pathology*; D004676:Myelin Basic Protein / Q000378:metabolism; D010739:Phospholipase D / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism; D058225:Plaque, Amyloid / Q000473:pathology; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000378:metabolism; D043882:Receptors, Cannabinoid / Q000378:metabolism*; D062826:Zonula Occludens-1 Protein
D000199:Actins; D018952:Antigens, CD34; D006684:HLA-DR Antigens; D008565:Membrane Proteins; D004676:Myelin Basic Protein; D010750:Phosphoproteins; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; C569042:TJP1 protein, human; D062826:Zonula Occludens-1 Protein; D018799:Intercellular Adhesion Molecule-1; D010739:Phospholipase D
Neurosci Lett. 2006 Mar 27;396(2):113-6
16356641
J Neurosci. 2007 Feb 28;27(9):2396-402
17329437
Biochem Pharmacol. 2006 Sep 28;72(7):869-80
16914119
J Comp Neurol. 2008 Feb 1;506(4):604-15
18067139
BMC Neurol. 2006 Mar 02;6:12
16512913
Neurobiol Dis. 2010 Jan;37(1):166-76
19815071
J Cardiovasc Pharmacol. 2004 Nov;44(5):517-9
15505486
J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1664-9
16291891
Lancet. 2002 Apr 6;359(9313):1221-31
11955556
J Neuroimmune Pharmacol. 2009 Jun;4(2):249-59
19255856
J Biol Chem. 2005 Oct 28;280(43):35797-806
16105834
Mult Scler. 2004 Apr;10(2):158-64
15124761
J Comp Neurol. 2008 Aug 1;509(4):400-21
18521853
Neuropathol Appl Neurobiol. 2007 Feb;33(1):86-98
17239011
Neurobiol Dis. 2005 Nov;20(2):207-17
16242629
Neurobiol Dis. 2006 May;22(2):257-64
16364651
Brain Res Mol Brain Res. 2004 Dec 6;132(1):87-92
15548432
J Neuroimmunol. 1999 Jul 1;98(1):49-56
10426362
J Neurosci. 2002 Nov 15;22(22):9742-53
12427829
Eur J Neurosci. 2000 Sep;12(9):3239-49
10998107
PLoS Genet. 2009 Feb;5(2):e1000369
19197344
J Neurosci. 2001 Feb 1;21(3):823-33
11157068
J Pathol. 2003 Oct;201(2):319-27
14517850
Mol Cell Neurosci. 2009 Feb;40(2):258-66
19059482
Curr Pharm Des. 2008;14(23):2326-36
18781983
FEBS Lett. 1998 Aug 14;433(1-2):139-42
9738948
Neuroscience. 2000;100(4):797-804
11036213
Lancet. 2003 Nov 8;362(9395):1517-26
14615106
Thromb Haemost. 2006 Jan;95(1):117-27
16543970
Brain. 2003 Oct;126(Pt 10):2191-202
12876144
Neurologist. 2007 Jul;13(4):182-7
17622909
Brain Res. 2006 Aug 30;1107(1):199-205
16822488
J Neurochem. 2005 Oct;95(2):437-45
16086683
J Neurosci. 2009 Sep 16;29(37):11511-22
19759299
FASEB J. 2003 Mar;17(3):529-31
12514108
FASEB J. 2005 Aug;19(10):1338-40
15941768
Nat Rev Cancer. 2003 Oct;3(10):745-55
14570037
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8
17660390
Mol Neurobiol. 2007 Aug;36(1):68-74
17952651
Neuroscience. 2008 Feb 19;151(4):955-68
18248904
Synapse. 2001 Sep 1;41(3):195-202
11391780
Brain. 2009 Dec;132(Pt 12):3196-8
20008341
Neurosci Lett. 2010 Feb 5;470(1):65-70
20036712
Neuron. 2006 Jan 5;49(1):67-79
16387640
Br J Pharmacol. 2007 Nov;152(5):649-54
17891167